Globe Life
GL
$151.65
-1.26%
Globe Life Inc. is a holding company that underwrites life insurance, supplemental health insurance, and annuities, distributing primarily through a large captive agent force and direct-to-consumer channels to middle-income American households; operations are organized into Life, Health, and Investment segments. It is a niche, distribution-driven underwriter rather than a broad financial platform — a steady, high-return-on-equity specialist competing against much larger life insurers and supplemental benefits carriers. The current investor debate centers on the durability of its underwriting margins after a volatile 2026 earnings cadence, the sustainability of its buyback-funded EPS growth, and a notable late-October share-price drawdown that coincided with a Piper Sandler downgrade to Neutral, even as most of the Street (Wells Fargo, JPMorgan, Morgan Stanley, TD Cowen) maintained constructive ratings. With only one analyst contributing to the quantitative estimate set, the stock sits in a coverage gap that amplifies headline sensitivity.…
GL
Globe Life
$151.65
Investment Opinion: Should I buy GL Today?
Rating: Hold (with a constructive value tilt). The core thesis is that Globe Life is a high-quality, capital-light underwriter trading at a genuine discount — 9.78x trailing earnings, 1.89x book, an 11.8% FCF yield ($1.33 billion TTM FCF on an ~$11.3 billion market cap), and a 19.4% ROE — but the market's multi-year de-rating (PE from 13.82x in Q4 2022 to 8.79x in Q3 2026) and the unfilled October 23 gap-down (168.41 to 154.79, -8.1%) mean there is no near-term catalyst forcing a re-rating. The qualitative sell-side stance is constructive — seven of ten recent actions are Buy/Overweight/Outperform (Wells Fargo, JPMorgan, Morgan Stanley, TD Cowen, KBW) with zero Sells — but with only one analyst in the quantitative estimate set and no published consensus price target, the implied upside cannot be calculated, which caps conviction.
Supporting evidence is strong on fundamentals: Q3 2026 revenue of $1.596 billion grew 5.48% year over year; net margin expanded to 22.63% from 17.99% in Q2 and 17.35% in Q1, with operating margin at 30.02% versus 23.60% in Q1; debt-to-equity is a conservative 0.44; and the company repurchased $218.0 million of stock in Q3 against just $25.4 million of dividends (payout ratio 7.4%), shrinking shares from 83.5 million in Q1 2025 to 78.2 million in Q3 2026. Against a typical life-insurer PE band of 10-13x, the 9.78x trailing multiple is a roughly 10-25% discount, and the 1.89x book multiple sits below the 2.0-2.5x many quality underwriters command — a discount that looks wider than a 19.4% ROE and 11.8% FCF yield justify.
Three risks could invalidate the thesis: (1) a second consecutive weak reported quarter or another downgrade breaking the 154.79 October close and opening the 149.87 May low; (2) continued multiple compression signaling the market is rationally discounting captive-agent regulatory/conduct risk rather than overreacting; and (3) buyback-funded EPS growth stalling if free cash flow decelerates, since revenue growth of 5.48% is modest. This Hold would upgrade to Buy on a reclaim of ~172 (neutralizing the October breakdown) or a confirmed margin trend above 22% net, and would downgrade to Sell on a break below 149.87 or a second analyst moving to Neutral. Verdict: fairly valued to modestly undervalued relative to history and peers — a value/GARP candidate, not a momentum trade.
Sign up to view all
GL 12-Month Price Forecast
Globe Life presents a classic value-versus-momentum tension: the fundamentals are improving (Q3 net margin 22.63%, operating margin 30.02%, $218 million of Q3 buybacks) while the stock has de-rated from 13.82x to 9.78x trailing earnings and sits at only ~30% of its 52-week range. The qualitative sell-side is constructive — seven of ten recent actions are Buy/Overweight with zero Sells — but the single-analyst quantitative coverage and the unfilled October 23 gap-down keep conviction capped. The base case (50%) is range-bound consolidation between 155 and 175 as the market waits for confirmation that margins hold and buybacks continue. I would upgrade to bullish on a reclaim of 172 with a confirmed margin trend above 22% net, and downgrade to bearish on a break below 149.87 or a second analyst moving to Neutral.
Wall Street consensus
Coverage is extremely thin: only one analyst contributes to the quantitative estimate set, with an average EPS estimate of $20.05 (range $19.86-$20.23) and average revenue of $7.50 billion (range $7.44-$7.55 billion). No consensus price target or Buy/Hold/Sell distribution is available in the provided data, so implied upside cannot be calculated — a material limitation. Qualitatively, the institutional ratings log is more informative and leans bullish: of ten recent actions, seven are Buy/Overweight/Outperform (Wells Fargo, JPMorgan, Morgan Stanley, TD Cowen, KBW), two are Neutral/In Line (Evercore, Piper Sandler), and none are Sell.\n\nThe signal strength is mixed. The ratings are overwhelmingly constructive and have been stable — repeated Overweight reiterations from Wells Fargo (Oct 12 and Oct 26), JPMorgan (Oct 15), and Morgan Stanley (Oct 5) — but the one directional change was negative: Piper Sandler cut to Neutral from Overweight on October 23, the same day the stock gapped down 8.1%, suggesting the downgrade was a catalyst rather than a coincident event. Without published targets, the high/low range cannot be characterized, but the combination of a single quantitative contributor and a wide EPS estimate band ($19.86-$20.23, a ~1.9% spread) signals low conviction in forward numbers. Limited coverage typically means less efficient price discovery and higher headline volatility — consistent with the October gap — and investors should weight the qualitative sell-side stance (constructive) against the quantitative coverage gap (thin) when sizing positions.
Bulls vs Bears: GL Investment Factors
The bear case currently has slightly stronger near-term evidence: the stock has lost 11.19% over three months, sits at roughly 30% of its 52-week range, and carries an unfilled October gap-down tied to a Piper Sandler downgrade, all while its PE has de-rated from 13.82x to 9.78x over four years. The bull case rests on harder fundamentals — a 19.4% ROE, 11.8% FCF yield, improving Q3 margins (22.63% net versus 17.35% in Q1), and aggressive buybacks ($218 million in Q3) — and is supported by seven of ten constructive analyst ratings with no Sells. The single most important tension is whether the market's persistent multiple compression reflects a rational discount for captive-agent regulatory risk and thin coverage, or an overreaction that improving margins and buybacks will eventually reverse; how that resolves determines whether GL is a value trap or a re-rating candidate.
Bullish
- Deep discount to sector PE: GL trades at 9.78x trailing earnings versus the 10-13x range typical for life insurers, a roughly 10-25% discount. With a 19.4% ROE and 11.8% FCF yield, the discount looks wider than the fundamentals justify.
- Margins inflecting sharply higher: Q3 2026 net margin reached 22.63% versus 17.99% in Q2 and 17.35% in Q1, while operating margin climbed to 30.02% from 23.60% in Q1. Gross margin of 56.51% in Q3 compares with 49.37% in Q1, showing real operating leverage.
- Buyback machine funds EPS growth: GL repurchased $218.0 million of stock in Q3 alone against just $25.4 million of dividends, with a payout ratio of only 7.4%. Shares outstanding fell from 83.5 million in Q1 2025 to 78.2 million in Q3 2026, mechanically lifting EPS.
- Fortress balance sheet and cash flow: Debt-to-equity is a conservative 0.44 and TTM free cash flow is $1.33 billion against an $11.3 billion market cap. Q3 operating cash flow of $325.8 million with only $14.9 million of capex leaves ample room for continued capital return.
Bearish
- October downgrade triggered 8.1% gap: Piper Sandler cut GL to Neutral from Overweight on October 23, the same day the stock gapped from 168.41 to 154.79, an 8.1% single-session drop. The gap remains largely unfilled at 160.74, a bearish technical signature.
- Multi-year valuation de-rating: PE has compressed from 13.82x in Q4 2022 to 10.57x in Q4 2023, 10.44x in Q4 2025, and 8.79x in Q3 2026, while PB fell from 2.96x to 1.89x. The market is steadily paying less for each dollar of earnings despite growth.
- Momentum has broken down: GL is down 11.19% over three months and 3.98% over one month, versus a 20.71% trailing-year gain, with relative strength of -8.36 points versus SPY over three months. The stock sits at only about 30% of its 52-week range.
- Dangerously thin analyst coverage: Only one analyst contributes to the quantitative estimate set, with an EPS band of $19.86-$20.23 (a ~1.9% spread) and no consensus price target available. This coverage gap amplifies headline sensitivity and impairs price discovery, as the October gap demonstrated.
GL Technical Analysis
Globe Life is in a choppy, range-bound consolidation rather than a clean trend. The stock is up 20.71% over the trailing year versus 12.27% for SPY (relative strength +8.44 points), and up 16.12% YTD, but it has surrendered much of its mid-summer gains: the 52-week closing range runs from roughly 149.87 (May 19 low) to 186.02 (August 6 high), and at 160.74 the stock sits at about 30% of that range — closer to the lower quartile than the highs, which signals loss of momentum rather than a value washout. The 16.79% max drawdown confirms a meaningful correction from the summer peak.\n\nShort-term momentum has clearly decelerated and diverged from the longer-term uptrend. The stock is down 3.98% over the past month and 11.19% over three months, versus a 1-year gain of 20.71% — a classic divergence where the trailing-year strength is being unwound by recent weakness. Relative strength tells the same story: -1.72 points versus SPY over one month and -8.36 points over three months, despite +5.50 YTD and +1.55 over six months. The sharpest damage came on October 23, when the stock gapped from 168.41 to 154.79 in a single session (an 8.1% one-day drop), and it has since rebuilt only to 160.74 — a partial recovery that leaves the October gap largely unfilled, a bearish technical signature.\n\nKey levels are well defined. Support sits at the 149.87 May low, with secondary support near the 154.79 October 23 gap-down close; resistance is the 186.02 August high, with an intermediate ceiling around 172-175 where the stock repeatedly stalled in September. A reclaim of 172 would neutralize the October breakdown; a break below 154.79 would confirm a lower-high/lower-low structure and open the May low. Volatility is meaningful: the 16.79% max drawdown and the single-day 8% gap argue for smaller position sizing, and with volume data unavailable (reported as 0), confirmation of any breakout should be treated cautiously until liquidity data can be verified.
Beta
—
—
Max Drawdown
-18.5%
Largest decline past year
52-Week Range
—
Price range past year
Annual Return
+16.3%
Cumulative gain past year
| Period | GL Return | S&P 500 |
|---|---|---|
| 1m | -10.6% | -9.7% |
| 3m | -11.4% | -9.9% |
| 6m | -3.0% | -7.5% |
| 1y | +16.3% | +4.7% |
| ytd | +9.6% | +1.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GL Fundamental Analysis
Revenue is growing at a modest but steady clip. Q3 2026 revenue was $1.596 billion, up 5.48% year over year from $1.513 billion in Q3 2025, and the sequential cadence has been consistent — $1.560 billion in Q1, $1.600 billion in Q2, $1.596 billion in Q3 — implying roughly $6.3 billion annualized. Segment disclosure shows Life at $864.6 million and Health at $446.9 million, meaning Life is the larger engine at roughly two-thirds of the disclosed premium base. Growth is respectable for a mature life insurer but not accelerating; the investment case rests more on margin and capital return than on top-line expansion.\n\nProfitability is solid and margins have been improving through 2026. Q3 2026 net income was $361.1 million on a 22.63% net margin, up from $287.7 million (17.99% margin) in Q2 and $270.5 million (17.35%) in Q1; the reported gross margin of 56.51% in Q3 compares with 49.37% in Q1 and a distorted negative print in Q2. Operating margin reached 30.02% in Q3 versus 23.60% in Q1, and the 19.43% ROE (key metrics) is healthy for the sector, though the quarterly historical ROE series (5.46% in Q3) reflects a different, partial-period calculation basis. Note that Q2's negative EBITDA and gross profit figures appear to be accounting artifacts from investment gains/losses flowing through the income statement rather than operating deterioration — the underlying pretax margin stayed in the 21-28% band all year.\n\nThe balance sheet and cash generation are the strongest part of the story. Debt-to-equity is a conservative 0.44, the current ratio is 9.66 (inflated by insurance-company accounting but still indicative of ample liquidity), and TTM free cash flow is $1.33 billion against a $11.3 billion market cap — a roughly 11.8% FCF yield. Q3 operating cash flow was $325.8 million with capex of only $14.9 million, and the company returned capital aggressively: $218.0 million of buybacks and $25.4 million of dividends in the quarter alone. The dividend is tiny relative to earnings (payout ratio 7.4%, yield 0.76%), leaving enormous room for continued repurchases — the primary EPS growth lever.
Quarterly Revenue
$1.6B
2026-09
Revenue YoY Growth
+5.5%
YoY Comparison
Gross Margin
56.5%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GL Overvalued?
Because net income is positive ($361.1 million in Q3 alone), the PE ratio is the appropriate primary metric. The trailing PE is 9.78x while the forward PE is reported at 0.51x — an implausibly wide gap that almost certainly reflects a data artifact (the forward figure appears to be a PEG-style or mis-scaled input rather than a true forward multiple). Using the more reliable consensus EPS estimate of $20.05 against the $160.74 price implies roughly 8.0x forward earnings, which is consistent with the trailing 9.78x and suggests the market is pricing modest single-digit growth with limited multiple expansion.\n\nOn peer comparison, Globe Life screens cheap across the board: PB of 1.89x, PS of 1.89x, EV/EBITDA of 8.66x, and a PEG of 0.51. Life insurers typically trade in the 10-13x PE range, so a 9.78x trailing multiple represents a discount of roughly 10-25% to the sector, and the 1.89x book multiple is below the 2.0-2.5x range many quality underwriters command. The discount is partly justified — single-analyst coverage, a captive-agent distribution model that carries regulatory and conduct risk, and a 0.76% dividend yield well below the sector's typical 2-3% — but the 19.4% ROE and 11.8% FCF yield argue the discount is wider than fundamentals warrant.\n\nHistorically, the stock's own PE band has compressed dramatically. The historical ratios show PE at 13.82x in Q4 2022, 10.57x in Q4 2023, 10.44x in Q4 2025, and 8.79x in Q3 2026 — a steady multi-year de-rating to the bottom of its range. PB has followed the same path, from 2.96x in Q4 2022 to 1.89x today. This is either a value opportunity (earnings have grown while the multiple shrank) or a signal that the market is discounting future growth and regulatory risk; the 11.19% three-month price decline despite improving Q3 margins suggests the market currently leans toward the latter.
PE
9.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 7x~15x
vs. Industry Avg
11.7x
Industry PE ~11.7x*
EV/EBITDA
8.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the durability of earnings quality and the buyback dependency. Q2 2026 reported negative EBITDA of -$629.6 million and negative gross profit of -$804.1 million, which appear to be accounting artifacts from investment gains/losses flowing through the income statement, but they illustrate how volatile reported results can be for an insurer with a large investment portfolio. Revenue growth is modest at 5.48% year over year, so EPS expansion leans heavily on share count reduction — shares fell from 83.5 million in Q1 2025 to 78.2 million in Q3 2026 — meaning any slowdown in free cash flow ($1.33 billion TTM) would directly throttle the primary growth lever. The business is also concentrated: Life segment premium of $864.6 million is roughly two-thirds of the disclosed base, leaving the company exposed to mortality experience and persistency in a single product line.
Market and competitive risks stem from persistent multiple compression and thin coverage. GL's PE has de-rated from 13.82x in Q4 2022 to 9.78x today and PB from 2.96x to 1.89x, a multi-year trend that has continued even as Q3 margins improved — a sign the market is discounting future growth and regulatory risk rather than rewarding current profitability. The captive-agent distribution model carries conduct and regulatory exposure that larger, diversified insurers with broader channel mixes do not face to the same degree. Coverage is a structural vulnerability: with only one analyst in the quantitative estimate set and no consensus price target, headline events move the stock disproportionately, as shown by the 8.1% single-day gap on October 23 tied to a Piper Sandler downgrade. The 0.76% dividend yield also makes GL less defensive than sector peers in a rotation toward income, and its 20.71% trailing-year gain versus SPY's 12.27% leaves room for profit-taking.
In a worst-case scenario, a second consecutive quarter of weak reported results or another downgrade would confirm the lower-high/lower-low structure and break the 154.79 October gap-down close, opening a path to the 149.87 May 2026 low. From the current $160.74, that represents roughly -6.8% to the October close and about -6.8% to the May low, while a fuller retracement toward the 16.79% max drawdown would imply a price near $133.75, or roughly -17% from current levels. If margin improvement reverses and the market re-rates the stock toward the bottom of its historical band, a decline into the low-to-mid $140s (-10% to -13%) is a realistic adverse outcome. The combination of thin coverage, an unfilled gap, and a stock already down 11.19% over three months means downside momentum could accelerate quickly on any negative catalyst.
FAQ
Ranked by severity, the first risk is earnings quality and buyback dependency: Q2 2026 reported negative EBITDA of -$629.6 million and negative gross profit of -$804.1 million from investment gains and losses flowing through the income statement, and with revenue growth of only 5.48%, EPS expansion leans on share count reduction funded by $1.33 billion of TTM free cash flow — any FCF slowdown throttles the main growth lever. Second is multiple compression: PE has fallen from 13.82x to 9.78x over four years and the stock is down 11.19% over three months despite improving Q3 margins, suggesting the market may be rationally discounting captive-agent regulatory risk rather than overreacting. Third is coverage and headline risk: with one quantitative analyst and no consensus target, the Piper Sandler downgrade to Neutral on October 23 coincided with an 8.1% single-session gap that remains unfilled. Fourth is concentration and income: Life premium of $864.6 million is roughly two-thirds of the disclosed base, and the 0.76% dividend yield is well below the 2-3% sector norm, leaving GL vulnerable to rotation toward higher-income financials.
The base case carries 50% probability and a $155-$175 range, assuming revenue growth holds near 5.5%, net margin stays in the low-20s, buybacks continue at $150-220 million per quarter, and the stock consolidates between the 154.79 October close and 172-175 September resistance. The bull case (25%) targets $186-$200, requiring a reclaim of 172 that fills the October gap, sustained 22-23% net margins, and multiple expansion toward the sector's 10-13x band on $20.05 of EPS. The bear case (25%) targets $134-$150, driven by a second weak quarter or another downgrade breaking 154.79 and the 149.87 May low, with a fuller retracement toward the 16.79% max drawdown implying roughly 133.75. The base case is most likely because the consensus EPS estimate of $20.05 at about 8x forward earnings already implies fair value near current levels, and there is no near-term catalyst forcing a re-rating.
GL screens undervalued on every relative metric in the dataset: 9.78x trailing PE, 1.89x price-to-book, 1.89x price-to-sales, 8.66x EV/EBITDA, and a PEG of 0.51. Life insurers typically command 10-13x earnings and 2.0-2.5x book, so the stock trades at roughly a 10-25% discount to the sector despite a 19.4% ROE. Against its own history the picture is more ambiguous: PE has compressed from 13.82x in Q4 2022 to 10.57x in Q4 2023, 10.44x in Q4 2025, and 8.79x in Q3 2026, with book falling from 2.96x to 1.89x — a steady multi-year de-rating even as earnings grew. That implies the market is pricing in either regulatory and conduct risk from the captive-agent model, thin coverage, or simply low expected growth, rather than mispricing. The verdict is fairly valued to modestly undervalued: cheap versus peers, but at the bottom of its own historical band for reasons the market has consistently endorsed.
The risk/reward is moderately attractive but not compelling enough for a Buy. On the positive side, GL trades at 9.78x trailing earnings and roughly 8x the $20.05 consensus EPS, versus a 10-13x band typical for life insurers, while generating a 19.4% ROE and an 11.8% FCF yield — a discount that looks wider than the fundamentals justify. The downside is quantifiable: a break of the 154.79 October close opens the 149.87 May low (about -6.8%), and a fuller retracement toward the 16.79% max drawdown implies roughly 133.75, or about -17%. Because only one analyst contributes to the quantitative set and no consensus price target exists, the upside cannot be anchored, and the 8.1% single-day gap on October 23 shows how violently thin coverage can reprice the stock. It is a reasonable buy for value-oriented investors with a 12-18 month horizon who can tolerate a 0.76% yield and headline volatility, and a poor fit for momentum or income buyers.
GL fits a medium-to-long-term holding period of at least 12-18 months, not a short-term trade. The thesis depends on a slow re-rating from 9.78x toward the 10-13x sector band and on continued buyback-driven EPS compounding, both of which play out over multiple quarters rather than weeks. Short-term trading is disadvantaged by the technical picture — an unfilled October 23 gap, a 16.79% max drawdown, and a stock at roughly 30% of its 52-week range — and by thin coverage that produces outsized single-day moves like the 8.1% gap. The 0.76% dividend yield offers almost no income cushion while waiting, so total return depends on price appreciation. A reasonable approach is to size positions modestly given the volatility, accumulate near the 149.87-154.79 support zone, and reassess on a reclaim of 172 or a confirmed margin trend above 22% net.

